PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
6.67%
Revenue growth under 50% of RUN's 17.15%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
-177.61%
Negative gross profit growth while RUN is at 30.76%. Joel Greenblatt would examine cost competitiveness or demand decline.
-80.71%
Negative EBIT growth while RUN is at 71.74%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
33.93%
Operating income growth under 50% of RUN's 71.74%. Michael Burry would be concerned about deeper cost or sales issues.
-76.09%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-75.00%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-75.00%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.08%
Share reduction more than 1.5x RUN's 1.03%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.08%
Slight or no buyback while RUN is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
83.73%
OCF growth above 1.5x RUN's 33.30%. David Dodd would confirm a clear edge in underlying cash generation.
56.28%
Positive FCF growth while RUN is negative. John Neff would see a strong competitive edge in net cash generation.
-35.00%
Negative 10Y revenue/share CAGR while RUN stands at 181.88%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-38.39%
Negative 5Y CAGR while RUN stands at 181.88%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
17.44%
3Y revenue/share CAGR under 50% of RUN's 117.37%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
-132.84%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-168.88%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
91.47%
3Y OCF/share CAGR above 1.5x RUN's 41.21%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-405.40%
Negative 10Y net income/share CAGR while RUN is at 84.42%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-709.40%
Negative 5Y net income/share CAGR while RUN is 84.42%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-19.28%
Negative 3Y CAGR while RUN is 64.65%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-111.66%
Negative equity/share CAGR over 10 years while RUN stands at 106.17%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-116.09%
Negative 5Y equity/share growth while RUN is at 106.17%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-113.86%
Negative 3Y equity/share growth while RUN is at 54.44%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13.76%
Firm’s AR is declining while RUN shows 5.78%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-19.52%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
-24.74%
Negative asset growth while RUN invests at 4.78%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-393.59%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-54.80%
We’re deleveraging while RUN stands at 9.76%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-0.80%
Our R&D shrinks while RUN invests at 14.94%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-29.30%
We cut SG&A while RUN invests at 3.11%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.